Aguiar-Lucander described Tarpeyo, its lead drug, as “beautiful, unique, but pretty simple,” adding that it has received accelerated FDA approval for treating IgA nephropathy, an autoimmune kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results